Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats.

Little is known about the influence of angiotensin converting enzyme (ACE) inhibitors on matrix metalloproteinase (MMP) in right ventricular remodeling. We investigated the effect of captopril, an ACE inhibitor, on MMP-2 and MMP-9 in monocrotaline-induced right ventricular hypertrophy. Six-week-old male Wistar rats were injected intraperitoneally with monocrotaline (60 mg/kg) or saline. The rats were administrated captopril (30 mg/kg per day) or a vehicle orally for 24 days from the day of monocrotaline injection. At day 25, echocardiography was performed and hearts were excised. Expressions and activities of MMP-2 and MMP-9 were measured by Western blotting and by gelatin zymography, respectively. In monocrotaline-injected rats, right ventricular weight/tail length ratio increased significantly. Histological analysis revealed cardiomyocyte hypertrophy and fibrosis in right ventricular sections. Echocardiography showed right ventricular dysfunction compared with saline-injected rats. The right ventricular hypertrophy, fibrosis, and dysfunction were inhibited by captopril. However, captopril did not attenuate an increase in pulmonary artery pressure. MMP-2 and MMP-9 expressions and activities in right ventricles increased significantly in monocrotaline-injected rats and captopril inhibited them. These findings indicate that captopril attenuates the development of monocrotaline-induced right ventricular hypertrophy in association with inhibition of MMP-2 and MMP-9 in rats.

[1]  A. Nadas,et al.  Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. , 1979, The American journal of physiology.

[2]  F. Ghodsi,et al.  Changes in pulmonary structure and function induced by monocrotaline intoxication. , 1981, The American journal of physiology.

[3]  M. Daemen,et al.  Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension. , 1998, American journal of respiratory and critical care medicine.

[4]  F. Spinale,et al.  A Matrix Metalloproteinase Induction/Activation System Exists in the Human Left Ventricular Myocardium and Is Upregulated in Heart Failure , 2000, Circulation.

[5]  M. Karmazyn,et al.  Attenuation of compensatory right ventricular hypertrophy and heart failure following monocrotaline-induced pulmonary vascular injury by the Na+-H+ exchange inhibitor cariporide. , 2001, The Journal of pharmacology and experimental therapeutics.

[6]  Y. Wu,et al.  Angiotensin-Converting Enzyme Inhibitor Preserves p21 and Endothelial Nitric Oxide Synthase Expression in Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats , 2001, Circulation.

[7]  F. Spinale,et al.  Matrix Metalloproteinase Inhibition Attenuates Left Ventricular Remodeling and Dysfunction in a Rat Model of Progressive Heart Failure , 2001, Circulation.

[8]  R. Körfer,et al.  Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP , 2002, Heart.

[9]  Yi Zhu,et al.  Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and cardiac remodelling , 2003, Clinical and experimental pharmacology & physiology.

[10]  G. Hasenfuss,et al.  Mechanical Load-Dependent Regulation of Gene Expression in Monocrotaline-Induced Right Ventricular Hypertrophy in the Rat , 2003, Circulation research.

[11]  A. Takeshita,et al.  Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. , 2003, American journal of physiology. Heart and circulatory physiology.

[12]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[13]  Norman Honbo,et al.  A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. , 2003, The Biochemical journal.

[14]  T. Yokoi,et al.  Progressive development of pulmonary hypertension leading to right ventricular hypertrophy assessed by echocardiography in rats. , 2003, Experimental animals.

[15]  Zhonglin Xie,et al.  Differential Regulation of Matrix Metalloproteinase-2 and -9 Expression and Activity in Adult Rat Cardiac Fibroblasts in Response to Interleukin-1β* , 2004, Journal of Biological Chemistry.

[16]  J. Schaper,et al.  Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. , 2004, Journal of the American College of Cardiology.

[17]  P. Steendijk,et al.  Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. , 2006, American journal of physiology. Heart and circulatory physiology.

[18]  M. Okada,et al.  Enhanced gene expression of myocardial matrix metalloproteinases 2 and 9 after acute treatment with doxorubicin in mice. , 2006, Pharmacological research.

[19]  Sung-Hoon Kim,et al.  Ochnaflavone inhibits TNF‐α‐induced human VSMC proliferation via regulation of cell cycle, ERK1/2, and MMP‐9 , 2006, Journal of cellular biochemistry.

[20]  H. Yamawaki,et al.  Cytotoxicity of water-soluble fullerene in vascular endothelial cells. , 2006, American journal of physiology. Cell physiology.

[21]  H. Tan,et al.  Sequence of echocardiographic changes during development of right ventricular failure in rat. , 2006, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[22]  S. Takai,et al.  Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. , 2006, Journal of pharmacological sciences.

[23]  Anne M Deschamps,et al.  Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. , 2006, Cardiovascular research.

[24]  D. Atsma,et al.  Activation of signaling molecules and matrix metalloproteinases in right ventricular myocardium of rats with pulmonary hypertension. , 2007, Pathology, research and practice.

[25]  A. Trafford,et al.  Spatial disruption and enhanced degradation of collagen with the transition from compensated ventricular hypertrophy to symptomatic congestive heart failure. , 2007, American journal of physiology. Heart and circulatory physiology.

[26]  Joseph S Janicki,et al.  Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. , 2007, American journal of physiology. Heart and circulatory physiology.

[27]  S. Takai,et al.  Inhibition of matrix metalloproteinase-9 activity by lisinopril after myocardial infarction in hamsters. , 2007, European journal of pharmacology.

[28]  Francis G Spinale,et al.  Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. , 2007, Physiological reviews.